Take Part Of The Next Anti-CTLA4 Explicyte Shuttle

05 / 19 / 2016

The comparison of the efficacy of a drug candidate with the gold standard anti-CTLA4 immunotherapy and/or evaluation of its ability to potentiate CTLA4 blockade mostly relies on immunocompetent mouse models in which the response to CTLA4 blockade has been already validated (see our recent case study).

In the next explicyte shuttle, we offer our clients to include experimental groups in an already scheduled study. In this session, explicyte will cover the costs of vehicle and anti-CTLA4 treated group and sponsor will only cover its experimental groups (eg. drug candidates alone or in combination with anti-CTLA4 mAb).

The next explicyte shuttle is scheduled for the 21th of June!
 

In Vivo Syngeneic Mouse Tumor Models – CT26 And 4T1 – With Differential Sensitivity To CTLA4 Blockade

  • Strain: Balb/c mice
  • Methods: Inoculation of tumor cells into immunocompetent mice
  • Readouts: Tumor growth / Body-weight / Survival
  • Standard reference : CTLA-4 monoclonal antibody
  • Experimental conditions: 10 animals per group
  • Turnaround time: 11-13 weeks

antiCTLA4-treat

Experimental design in the next anti-CTLA4 explicyte shuttle.  Naive balb/c immunocompetent mice are inoculated with tumor cells (CT26 or 4T1) and are then exposed to anti-CTLA4 monoclonal antibody at days 3, 6 and 9 after inoculation. Based on this standard experimental protocol, sponsors can build different experimental groups where a drug candidate can be compared to the anti-CTLA4 mAb or evaluated for its ability to synergize with the CTLA4 blocker. Efficacy study can be complemented with immune features analysis (flow cytometry, RT-qPCR) at different sites (spleen, tumor draining lymph nodes, tumor).